MSH6 and neoplasm: We report a case in which a patient with rapidly progressive metastatic castrate-resistant prostate cancer (mCRPC) was found to have an MSH6 mutation with microsatellite instability (MSI) and notably high tumor mutational burden (TMB) 109 mut/Mb, who had a complete response to pembrolizumab.